サルコイドーシスの世界市場レポート 2025年

サルコイドーシス市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は15.6%で、614億5,000万米ドルに成長します。予測期間中の成長は、新規生物学的療法に対する需要の高まり、個別化医療アプローチの採用拡大、サルコイドーシスに対する遺伝子治療への投資の増加、標的免疫療法開発への注目の高まり、難治性サルコイドーシス症例に対する治療薬パイプラインの拡大など、いくつかの要因によって牽引されると予想されます。予測期間中に予想される主な動向には、生物学的療法の進歩、ナノテクノロジーに基づくドラッグデリバリーシステムの進歩、再生医療と幹細胞治療の開発、3Dイメージングとラジオミクスの革新、臨床データ管理におけるブロックチェーン技術の統合などが含まれます。

個別化医療が重視されるようになったことで、サルコイドーシス市場の今後の成長が期待されます。個別化医療は、遺伝的体質、バイオマーカー、環境要因、ライフスタイルに基づいて個々の患者に合わせて治療戦略を調整し、より正確で効果的、かつ的を絞った介入を保証する先進的な医療アプローチです。個人の生物学的プロファイルに合わせて治療をカスタマイズすることで、有効性を高め、副作用を最小限に抑えることができるため、個別化医療への需要が高まっています。サルコイドーシスの場合、個別化医療は遺伝子、バイオマーカー、臨床プロファイリングに基づいて治療を調整し、有効性を高め、副作用を軽減します。この方法は、標的治療を強化し、疾患の不均一性に対処し、個々の患者のニーズに対応します。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、米国食品医薬品局（FDA）が2023年に希少疾患に対する新たな個別化治療を16件承認し、2022年のわずか6件から増加したと報告しました。その結果、個別化医療への注目の高まりがサルコイドーシス市場の成長を後押ししています。

サルコイドーシス市場で事業を展開する主な企業は、抗TNFaモノクローナル抗体療法などの最先端の治療法の開発に取り組んでおり、炎症性疾患の治療におけるアンメット・メディカル・ニーズに対応する新たな生物学的ソリューションを提供しています。抗腫瘍壊死因子α（抗TNFa）モノクローナル抗体療法は、モノクローナル抗体を用いて炎症性サイトカインであるTNFaをブロックすることで、炎症を抑え、自己免疫疾患を管理する標的免疫療法です。例えば、米国を拠点とする臨床段階のバイオセラピューティクス企業であるXentria, Inc.は、2023年11月、同社の主要候補であるXTMAB-16が欧州医薬品庁（EMA）から希少疾病用医薬品の指定を受けるという重要なマイルストーンを達成しました。また、肺サルコイドーシスを対象とした世界臨床試験を開始し、最初の患者を登録しました。TNFaを標的とするモノクローナル抗体であるXTMAB-16は、肺サルコイドーシスの炎症経路を制御し、副腎皮質ステロイドをベースとする治療に代わる標的を提供する可能性について研究されています。このような規制当局の承認と臨床の進展は、希少疾患に対する革新的な生物学的製剤に対する世界の関心の高まりを強調するものであり、革新的な治療でアンメット・メディカル・ニーズを満たすというゼントリアのコミットメントを強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のサルコイドーシス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のサルコイドーシス市場：成長率分析
• 世界のサルコイドーシス市場の実績：規模と成長、2019年～2024年
• 世界のサルコイドーシス市場の予測：規模と成長、2024年～2029年、2034年
• 世界のサルコイドーシス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のサルコイドーシス市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 肺サルコイドーシス
• 眼球サルコイドーシス
• 神経サルコイドーシス
• 心臓サルコイドーシス
• 筋骨格系サルコイドーシス
• 皮膚のサルコイドーシス
• 腎臓サルコイドーシス
• 肝臓のサルコイドーシス
• 脾臓と骨髄のサルコイドーシス
• 世界のサルコイドーシス市場：診断方法別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 画像技術
• 生検
• 血液検査
• 世界のサルコイドーシス市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• コルチコステロイド
• 免疫抑制剤
• 生物学的製剤
• 抗マラリア薬
• 世界のサルコイドーシス市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• オーラル
• 非経口
• その他の投与経路
• 世界のサルコイドーシス市場：最終用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院と診療所
• 外科センター
• 診断センター
• その他の用途
• 世界のサルコイドーシス市場、肺サルコイドーシスの病型別分類、実績と予測、2019年～2024年、2024年～2029年、2034年
• 急性肺疾患サルコイドーシス
• 慢性肺疾患サルコイドーシス
• 線維性肺疾患サルコイドーシス
• 世界のサルコイドーシス市場、眼球サルコイドーシスの分類（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 前部ぶどう膜炎
• 後部ぶどう膜炎
• 中間ぶどう膜炎
• ぶどう膜炎
• 視神経症
• 世界のサルコイドーシス市場、神経サルコイドーシスの分類（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 髄膜神経サルコイドーシス
• 脳神経サルコイドーシス
• 末梢神経障害
• 脊髄障害
• 視床下部-下垂体障害
• 世界のサルコイドーシス市場、心臓サルコイドーシスの病型別分類、実績と予測、2019年～2024年、2024年～2029年、2034年
• 房室ブロック
• 心室性不整脈
• 心不全
• 心筋炎
• 突然の心停止
• 世界のサルコイドーシス市場、筋骨格系サルコイドーシスの分類（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 関節炎
• ミオパチー
• 骨病変
• 世界のサルコイドーシス市場、皮膚サルコイドーシスの病型別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 狼瘡性狼瘡
• 結節性紅斑
• 丘疹サルコイドーシス
• プラークサルコイドーシス
• 皮下サルコイドーシス
• 世界のサルコイドーシス市場、腎臓サルコイドーシスの病型別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 肉芽腫性間質性腎炎
• 腎石灰化症
• 高カルシウム尿症誘発性腎臓疾患
• 世界のサルコイドーシス市場、肝臓サルコイドーシスの病型別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 肉芽腫性肝炎
• 門脈圧亢進症
• 肝線維症
• 世界のサルコイドーシス市場、脾臓と骨髄のサルコイドーシスのサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 脾腫
• 汎血球減少症
• 骨髄肉芽腫

第7章 地域別・国別分析

• 世界のサルコイドーシス市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のサルコイドーシス市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サルコイドーシス市場：競合情勢
• サルコイドーシス市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Fresenius Kabi USA LLC
• AstraZeneca plc
• GlaxoSmithKline plc（GSK）
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Regeneron Pharmaceuticals Inc.
• UCB Pharma
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Xentria Inc.
• Molecure SA
• Relief Therapeutics Holding AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サルコイドーシス市場2029年：新たな機会を提供する国
• サルコイドーシス市場2029年：新たな機会を提供するセグメント
• サルコイドーシス市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sarcoidosis is a complex inflammatory condition marked by the formation of granulomas small clusters of immune cells that can develop in various organs, most commonly the lungs and lymph nodes. This can lead to organ dysfunction, respiratory problems, or other systemic issues. While the exact cause remains unknown, it is thought to involve an abnormal immune response triggered by environmental or genetic factors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

There are several types of sarcoidosis, including pulmonary, ocular, neurosarcoidosis, cardiac, musculoskeletal, cutaneous, renal, hepatic, and sarcoidosis affecting the spleen and bone marrow. Pulmonary sarcoidosis, specifically, is a chronic inflammation of the lungs characterized by granuloma formation, which may result in symptoms such as cough, shortness of breath, and lung fibrosis if not managed properly. Diagnosing these conditions involves various methods, such as imaging techniques, biopsies, and blood tests. Treatment options include corticosteroids, immunosuppressive medications, biologics, and anti-malarial drugs, which can be administered through different routes such as oral or parenteral. These treatments are commonly used in hospitals, clinics, surgical centers, and diagnostic facilities.

The sarcoidosis market research report is one of a series of new reports from The Business Research Company that provides sarcoidosis market statistics, including sarcoidosis industry global market size, regional shares, competitors with a sarcoidosis market share, detailed sarcoidosis market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis industry. This sarcoidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sarcoidosis market size has grown rapidly in recent years. It will grow from$29.75 billion in 2024 to $34.46 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth observed in the historic period can be attributed to several factors, including heightened awareness of sarcoidosis among healthcare professionals, an increase in the prevalence of the disease in developed countries, the widespread use of corticosteroid-based treatments as the primary therapy, greater research funding for rare diseases, and a growing number of clinical trials focused on sarcoidosis treatments.

The sarcoidosis market size is expected to see rapid growth in the next few years. It will grow to$61.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth during the forecast period is expected to be driven by several factors, including a rising demand for novel biologic therapies, greater adoption of personalized medicine approaches, increased investments in gene therapy for sarcoidosis, a growing focus on targeted immunotherapy developments, and the expansion of drug pipelines for treating refractory sarcoidosis cases. Key trends anticipated in the forecast period include advancements in biologic therapies, progress in nanotechnology-based drug delivery systems, developments in regenerative medicine and stem cell therapy, innovations in 3D imaging and radiomics, and the integration of blockchain technology in clinical data management.

The growing emphasis on personalized medicine is expected to drive the growth of the sarcoidosis market in the future. Personalized medicine is an advanced medical approach that tailors treatment strategies to individual patients based on their genetic makeup, biomarkers, environmental factors, and lifestyle, ensuring more precise, effective, and targeted interventions. The demand for personalized medicine is increasing as it allows for treatments that are customized to an individual's biological profile, enhancing effectiveness and minimizing side effects. In the case of sarcoidosis, personalized medicine tailors treatment based on genetic, biomarker, and clinical profiling to improve efficacy and reduce adverse effects. This method enhances targeted therapy, addressing the disease's heterogeneity and responding to individual patient needs. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, up from just 6 treatments in 2022. As a result, the increasing focus on personalized medicine is boosting the growth of the sarcoidosis market.

Key companies operating in the sarcoidosis market are working on developing cutting-edge treatments, such as anti-TNFa monoclonal antibody therapy, to provide a novel biologic solution to address unmet medical needs in treating inflammatory diseases. Anti-tumor necrosis factor-alpha (anti-TNFa) monoclonal antibody therapy is a targeted immunotherapy that uses monoclonal antibodies to block TNFa, a pro-inflammatory cytokine, thereby reducing inflammation and managing autoimmune diseases. For instance, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, achieved a significant milestone when its lead candidate, XTMAB-16, received Orphan Drug Designation from the European Medicines Agency (EMA). The company also launched a global clinical study for pulmonary sarcoidosis, enrolling the first patient. XTMAB-16, a monoclonal antibody targeting TNFa, is being studied for its potential to regulate inflammatory pathways in pulmonary sarcoidosis, providing a targeted alternative to corticosteroid-based therapies. This regulatory recognition and clinical progress highlight the growing global interest in innovative biologics for rare diseases, emphasizing Xentria's commitment to meeting unmet medical needs with transformative treatments.

In June 2023, Xentria Inc., a US-based biotherapeutics company, entered into a partnership with Meitheal Pharmaceuticals Inc. to speed up the development and commercialization of XTMAB-16. Under this collaboration, Meitheal Pharmaceuticals obtained exclusive commercialization rights for XTMAB-16 in North America, while Xentria continued to lead the clinical development and regulatory progress. This partnership aims to increase market access and improve treatment options for patients with pulmonary sarcoidosis by leveraging Xentria's expertise in biologics and Meitheal's strong commercialization capabilities. Meitheal Pharmaceuticals, Inc. is a US-based biopharmaceutical company that specializes in developing and commercializing generic injectables, fertility treatments, biologics, and branded products.

Major players in the sarcoidosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Fresenius Kabi USA LLC, AstraZeneca plc, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., UCB Pharma, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc., Molecure SA, and Relief Therapeutics Holding AG.

Europe was the largest region in the sarcoidosis market in 2024. The regions covered in sarcoidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sarcoidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcoidosis market includes revenues earned by entities by providing services such as diagnostic tests, laboratory testing, gene therapies, disease management services, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcoidosis market also includes sales of corticosteroids, immunosuppressive agents, and antimalarial drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sarcoidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sarcoidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sarcoidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarcoidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pulmonary Sarcoidosis; Ocular Sarcoidosis; Neurosarcoidosis; Cardiac Sarcoidosis; Musculoskeletal Sarcoidosis; Cutaneous Sarcoidosis; Renal Sarcoidosis; Hepatic Sarcoidosis; Sarcoidosis Of The Spleen And Bone Marrow
• 2) By Diagnostic Method: Imaging Technique; Biopsy; Blood Tests
• 3) By Treatment Type: Corticosteroids; Immunosuppressive Agents; Biologics; Anti-Malarial Drugs
• 4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 5) By End Uses: Hospitals And Clinics; Surgical Centers; Diagnostic Centers; Other End Uses
• Subsegments:
• 1) By Pulmonary Sarcoidosis: Acute Pulmonary Sarcoidosis; Chronic Pulmonary Sarcoidosis; Fibrotic Pulmonary Sarcoidosis
• 2) By Ocular Sarcoidosis: Anterior Uveitis; Posterior Uveitis; Intermediate Uveitis; Panuveitis; Optic Neuropathy
• 3) By Neurosarcoidosis: Meningeal Neurosarcoidosis; Cranial Nerve Neurosarcoidosis; Peripheral Neuropathy; Spinal Cord Involvement; Hypothalamic-Pituitary Involvement
• 4) By Cardiac Sarcoidosis: Atrioventricular Block; Ventricular Arrhythmias; Heart Failure; Myocarditis; Sudden Cardiac Arrest
• 5) By Musculoskeletal Sarcoidosis: Arthritis; Myopathy; Bone Lesions
• 6) By Cutaneous Sarcoidosis: Lupus Pernio; Erythema Nodosum; Papular Sarcoidosis; Plaque Sarcoidosis; Subcutaneous Sarcoidosis
• 7) By Renal Sarcoidosis: Granulomatous Interstitial Nephritis; Nephrocalcinosis; Hypercalciuria-Induced Kidney Disease
• 8) By Hepatic Sarcoidosis: Granulomatous Hepatitis; Portal Hypertension; Hepatic Fibrosis
• 9) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly; Pancytopenia; Bone Marrow Granulomas
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sarcoidosis Market Characteristics

3. Sarcoidosis Market Trends And Strategies

4. Sarcoidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sarcoidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sarcoidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sarcoidosis Market Growth Rate Analysis
• 5.4. Global Sarcoidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sarcoidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sarcoidosis Total Addressable Market (TAM)

6. Sarcoidosis Market Segmentation

• 6.1. Global Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pulmonary Sarcoidosis
• Ocular Sarcoidosis
• Neurosarcoidosis
• Cardiac Sarcoidosis
• Musculoskeletal Sarcoidosis
• Cutaneous Sarcoidosis
• Renal Sarcoidosis
• Hepatic Sarcoidosis
• Sarcoidosis Of The Spleen And Bone Marrow
• 6.2. Global Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Technique
• Biopsy
• Blood Tests
• 6.3. Global Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Agents
• Biologics
• Anti-Malarial Drugs
• 6.4. Global Sarcoidosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.5. Global Sarcoidosis Market, Segmentation By End Uses, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Surgical Centers
• Diagnostic Centers
• Other End Uses
• 6.6. Global Sarcoidosis Market, Sub-Segmentation Of Pulmonary Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Pulmonary Sarcoidosis
• Chronic Pulmonary Sarcoidosis
• Fibrotic Pulmonary Sarcoidosis
• 6.7. Global Sarcoidosis Market, Sub-Segmentation Of Ocular Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis
• Optic Neuropathy
• 6.8. Global Sarcoidosis Market, Sub-Segmentation Of Neurosarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningeal Neurosarcoidosis
• Cranial Nerve Neurosarcoidosis
• Peripheral Neuropathy
• Spinal Cord Involvement
• Hypothalamic-Pituitary Involvement
• 6.9. Global Sarcoidosis Market, Sub-Segmentation Of Cardiac Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atrioventricular Block
• Ventricular Arrhythmias
• Heart Failure
• Myocarditis
• Sudden Cardiac Arrest
• 6.10. Global Sarcoidosis Market, Sub-Segmentation Of Musculoskeletal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arthritis
• Myopathy
• Bone Lesions
• 6.11. Global Sarcoidosis Market, Sub-Segmentation Of Cutaneous Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lupus Pernio
• Erythema Nodosum
• Papular Sarcoidosis
• Plaque Sarcoidosis
• Subcutaneous Sarcoidosis
• 6.12. Global Sarcoidosis Market, Sub-Segmentation Of Renal Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatous Interstitial Nephritis
• Nephrocalcinosis
• Hypercalciuria-Induced Kidney Disease
• 6.13. Global Sarcoidosis Market, Sub-Segmentation Of Hepatic Sarcoidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatous Hepatitis
• Portal Hypertension
• Hepatic Fibrosis
• 6.14. Global Sarcoidosis Market, Sub-Segmentation Of Sarcoidosis Of The Spleen And Bone Marrow, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Splenomegaly
• Pancytopenia
• Bone Marrow Granulomas

7. Sarcoidosis Market Regional And Country Analysis

• 7.1. Global Sarcoidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sarcoidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sarcoidosis Market

• 8.1. Asia-Pacific Sarcoidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sarcoidosis Market

• 9.1. China Sarcoidosis Market Overview
• 9.2. China Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sarcoidosis Market

• 10.1. India Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sarcoidosis Market

• 11.1. Japan Sarcoidosis Market Overview
• 11.2. Japan Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sarcoidosis Market

• 12.1. Australia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sarcoidosis Market

• 13.1. Indonesia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sarcoidosis Market

• 14.1. South Korea Sarcoidosis Market Overview
• 14.2. South Korea Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sarcoidosis Market

• 15.1. Western Europe Sarcoidosis Market Overview
• 15.2. Western Europe Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sarcoidosis Market

• 16.1. UK Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sarcoidosis Market

• 17.1. Germany Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sarcoidosis Market

• 18.1. France Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sarcoidosis Market

• 19.1. Italy Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sarcoidosis Market

• 20.1. Spain Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sarcoidosis Market

• 21.1. Eastern Europe Sarcoidosis Market Overview
• 21.2. Eastern Europe Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sarcoidosis Market

• 22.1. Russia Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sarcoidosis Market

• 23.1. North America Sarcoidosis Market Overview
• 23.2. North America Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sarcoidosis Market

• 24.1. USA Sarcoidosis Market Overview
• 24.2. USA Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sarcoidosis Market

• 25.1. Canada Sarcoidosis Market Overview
• 25.2. Canada Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sarcoidosis Market

• 26.1. South America Sarcoidosis Market Overview
• 26.2. South America Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sarcoidosis Market

• 27.1. Brazil Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sarcoidosis Market

• 28.1. Middle East Sarcoidosis Market Overview
• 28.2. Middle East Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sarcoidosis Market

• 29.1. Africa Sarcoidosis Market Overview
• 29.2. Africa Sarcoidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sarcoidosis Market, Segmentation By Diagnostic Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sarcoidosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sarcoidosis Market Competitive Landscape And Company Profiles

• 30.1. Sarcoidosis Market Competitive Landscape
• 30.2. Sarcoidosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Sarcoidosis Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Fresenius Kabi USA LLC
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline plc (GSK)
• 31.5. Eli Lilly and Company
• 31.6. Boehringer Ingelheim GmbH
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. UCB Pharma
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Cipla Ltd.
• 31.11. Lupin Limited
• 31.12. Mallinckrodt Pharmaceuticals
• 31.13. Xentria Inc.
• 31.14. Molecure SA
• 31.15. Relief Therapeutics Holding AG

32. Global Sarcoidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sarcoidosis Market

34. Recent Developments In The Sarcoidosis Market

35. Sarcoidosis Market High Potential Countries, Segments and Strategies

• 35.1 Sarcoidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sarcoidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sarcoidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34960_Sarcoidosis_GMR_2025